Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
2018 First Quarter results presentation
Operating income, growth figures, profitability and how our products have behaved.
Wed, 25/04/2018 - 12:15
0 min
Download related document
Select rating
Give 2018 First Quarter results presentation 1/5
Give 2018 First Quarter results presentation 2/5
Give 2018 First Quarter results presentation 3/5
Give 2018 First Quarter results presentation 4/5
Give 2018 First Quarter results presentation 5/5
No votes yet
Related
Moderna and ROVI expand long-term collaboration for the manufacture of mRNA...
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Laboratorios...
2 min
16/02/2022
ROVI receives the European Commission’s approval of Okedi® as a treatment for...
Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the European Commission has authorised the...
3 min
15/02/2022
Grant of partially reimbursable aid for the assessment of toxicity in...
Madrid - January 28, 2022 Last May, ROVI signed a financing agreement with the Centre for Industrial Technological Development...
1 min
28/01/2022
See More
Email
Facebook
Twitter
LinkedIn